AI Article Synopsis
- * It included over 85,000 participants, revealing an anti-HEV IgG prevalence of 18.02% and an incidence rate of HEV seroconversion of 1.79 per 100 person-years during a median follow-up of 1.2 years.
- * Key risk factors for HEV seroconversion identified include being 60 or older, low socioeconomic status, and residing in coastal areas or regions with high drainage density and anti-HEV IgG prevalence.
Article Abstract
Background And Aims: China is an endemic area for hepatitis E virus (HEV) infection. Estimating the prevalence and incidence of HEV infection in China plays a pivotal role in informing public health policies to prevent and control hepatitis E. This study aimed to investigate the prevalence of anti-HEV IgG and incidence of HEV seroconversion in China.
Methods: This study was based on the Meinian health check-up database in China. Participants who underwent testing for anti-HEV IgG at check-up centers in 24 provinces between 2017 and 2022 were included. In the cross-sectional analyses, overall prevalence and stratified prevalence in subpopulations with various characteristics were estimated and standardized according to the 2020 census of the Chinese population. In the longitudinal analyses, the occurrence of anti-HEV IgG positivity during the follow-up was defined as an incident HEV seroconversion. Overall and stratified incidence rates were estimated and expressed as per 100 person-years. Poisson regression was used to explore risk factors associated with HEV seroconversion.
Results: A total of 85,238 and 11,154 participants were included in the cross-sectional and longitudinal analyses, respectively. The prevalence of anti-HEV IgG in the general population was 18.02%. During a median follow-up of 1.2 years, the incidence rate of HEV seroconversion was 1.79 per 100 person-years. Age ≥60 years, low socioeconomic status, living in coastal areas, living in areas with high drainage density, and living in areas with high anti-HEV IgG prevalence were independent risk factors for HEV seroconversion.
Conclusions: Our findings would help inform policymaking for hepatitis E prevention and control in China as well as in other endemic regions of the world.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.cgh.2024.07.026 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Immunogenicity and safety of HepE Hecolin® in chronic hepatitis B patients at clinically stable stage: An open-label study in China.
Hum Vaccin Immunother
December 2025
Academy of Preventive Medicine, Shandong University, Jinan, China.
Acute hepatitis E infection could induce severe outcomes among chronic hepatitis B (CHB) patients. Between 2016 and 2017, an open-label study was conducted to evaluate the immunogenicity and safety of hepatitis E vaccine (HepE) in CHB patients, using healthy adults as parallel controls in China. Eligible participants who were aged ≥30 y were enrolled in the study.
View Article and Find Full Text PDFSeroprevalence of Hepatitis E Virus Among Schistosomiasis mansoni Patients Residing in Endemic Zone in Brazil.
Trop Med Infect Dis
December 2024
Postgraduate Program in Tropical Medicine, Center of Medical Sciences, Universidade Federal de Pernambuco (UFPE), Recife 50670-420, PE, Brazil.
The occurrence of hepatitis E virus (HEV) in patients with Schistosomiasis mansoni (SM) is still poorly understood in Brazil. The objective of this study was to estimate the seroprevalence of anti-HEV IgG in patients with SM and its association with the periportal fibrosis (PPF), assessed by serum markers and ultrasound criteria. This cross-sectional study was carried out in an endemic area in Pernambuco, Brazil, with schistosomal patients who underwent coproscopic survey.
View Article and Find Full Text PDFGeospatial distribution of Hepatitis E seroprevalence in Nepal, 2021.
PLoS Negl Trop Dis
December 2024
International Vaccine Institute, Seoul, Republic of Korea.
Background: Hepatitis E virus (HEV) causes acute jaundice and poses an important public health problem in low- and middle-income countries. Limited surveillance capacity and suboptimal access to diagnostics leads to under-reporting of HEV infections in affected countries, including Nepal. Serum antibodies against HEV are indicative of past infection.
View Article and Find Full Text PDFIncidence and risk factors of hepatitis E virus infection in women with gynecological tumors in Eastern China.
PeerJ
December 2024
Department of Surgery, The Affiliated Hospital of Qingdao University, Qingdao, China.
Background: Recently, there has been increasing interest in the exploration of the association between the hepatitis E virus () infection and malignancies; however, epidemiological data for infection among women with a gynecological tumors (GT) are limited. Herein, we investigated the correlation between and GT in Chinese women.
Methods: We recruited 452 women diagnosed with a primary GT and 452 healthy volunteers to investigate the possible routes and risk factors for infection.
Persistence of hepatitis E vaccine-induced antibody response across different dosage schedules and baseline serostatus.
NPJ Vaccines
December 2024
State Key Laboratory of Vaccines for Infectious Diseases, Xiang An Biomedicine Laboratory, School of Public Health, Xiamen University, Xiamen, China.
Hepatitis E virus (HEV) infection is a major cause of acute viral hepatitis worldwide. The efficacy and safety of the HEV239 vaccine have been validated, with protection lasting at least 10 years. This study extended the phase 3 trial of HEV239 (NCT01014845), presenting data on the durability of the anti-HEV IgG response elicited by one or two doses in the participants with different baseline serostatus.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!